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however, 14% of the women had had their first
mammogram after receiving their genetic test result.
Uptake rates were similar across the 3 geographic
areas: 99% of the women from Ontario (165 of 167),
93% of the women from Western Canada (52 of 56) and
93% of the women from Quebec (11 of 119) reported
undergoing mammography.
Interpretation
We have reported on the rates of uptake of various
cancer prevention options among Canadian women
with a BRCA1 or BRCA2 mutation. Approximately two-
thirds of women from Quebec had not taken up any
preventive option, compared with approximately one-
third of women from Western Canada and Ontario. The
greatest differences in uptake rates were observed with
prophylactic mastectomy. Women from Western
Canada had the highest uptake of prophylactic
mastectomy (46%), followed by women from Ontario
(22%), and Quebec (8%). We also observed
pronounced differences in rates of uptake of
prophylactic oophorectomy. Sixty-seven percent of
women from Western Canada and 61% of women from
Ontario had undergone preventive oophorectomy.
Again, fewer women from Quebec elected to have this
preventive surgery (39%). Overall, the uptake rates of
various preventive modalities were similar to those
reported in other countries.[11,12,14–18] The
surprising result was the great difference in uptake of
preventive options depending on where a woman
received her genetic counselling and testing.
Our results, and those of others, suggest that there
are wide variations in the uptake of preventive options
among BRCA1 and BRCA2 mutation carriers. The
differences in uptake could be due to a number of
factors, including health care professionals’ acceptance
and recommendation of the procedures, cultural
differences that influence patient preferences, and
access (including cost and availability).
Health care professionals’ acceptance and
recommendations clearly influence uptake. There is
evidence that physicians have differing opinions on the
various preventive options available to women with a
BRCA1 or BRCA2 mutation. In the United States, a
greater proportion of plastic surgeons (84.6%) than
general surgeons (47.0%) or gynecologists (38.3%) in
Maryland agreed that bilateral prophylactic
mastectomy has a role in the care of women at high risk
of developing breast cancer.
19 In France, only 11% of
physicians found it acceptable to propose prophylactic
mastectomy to women with a BRCA mutation.
20
Peshkin and colleagues surveyed physicians regarding
recommendations for tamoxifen for primary breast
cancer prevention and reported that physicians were
more likely to recommend tamoxifen to BRCA2
carriers (73%) than to BRCA1 carriers (57%)(p <
0.0001).
21 They concluded that physicians were not
convinced of the benefits of tamoxifen in BRCA1 and
BRCA2 mutation carriers. Although this research did
not examine women’s uptake of preventive options
with respect to their physician’s preference, it is
expected that physicians would influence their patients’
choices.
Cultural influences may also be responsible for
some of the discrepancies that we observed. Other
authors have examined the differences in uptake of
preventive options in various countries. Bouchard and
colleagues surveyed women from Canada (Quebec),
France and Great Britain about their medical decisions
related to BRCA1 and BRCA2 mutation testing and
found differences in the uptake of preventive
procedures in the 3 countries, which they attributed to
cultural differences.
22 Previous single-country follow-
up studies of BRCA1 and BRCA2 mutation carriers
have reported various rates of uptake of all of the
preventive options.
11,12,14-18 When the single-country
uptake rates are compared across countries, noticeable
differences in uptake are observed. This suggests that
variations between countries could be due to cultural
influences.
Access to services may also contribute to the
observed differences, particularly in the case of uptake
of MRI screening. To date, screening MRI is offered on
a research basis and is not widely available as a clinicalResearch Metcalfe et al
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service. Women with access to research studies are
more likely to have MRI for screening. The differences
in tamoxifen uptake may also be due to access issues,
including cost. Currently, tamoxifen costs
approximately $25 per month. Some women may not
have drug coverage and therefore may not be able to
afford this drug. The differences in surgical uptake that
we observed are probably not due to differences in
access across the country. Canadian women have
coverage for prophylactic surgeries, including breast
reconstruction, without cost. This would not be the
case in the United States, where differences in uptake
of preventive procedures have been attributed to
financial constraints. For example, Schwartz and
colleagues attributed the low rate of prophylactic
oophorectomy they observed to the constrained
financial resources of their study subjects.
23
Study limitations. The study participants were women
who had been found to carry a BRCA1 or BRCA2
mutation at one of 12 specialized genetic counseling
centres in Canada between 1995 and 2003. Although
ours is a relatively large sample (672 women), it may
not be representative of all women who have received a
positive genetic test result in Canada. Canadian women
may have undergone genetic testing in centres other
than the ones included here and we do not have any
information on their uptake of cancer prevention
options. Patterns of practice have evolved since 1999,
the average time at which our study subjects received
their genetic testing. We believe that genetic services
are now better integrated with surgical care and that
physician attitudes may have changed with regard to
specific preventive measures. It is our intention to
repeat this survey in 5 years to evaluate trends in
clinical practice.
We have described the significant differences in
uptake of preventive options by women with a BRCA1
or BRCA2 mutation who have received genetic testing
in different areas of one country. The differences
cannot be explained by differing health care systems
because Canada has a universal health care system: all
of the women in this study had similar access to health
care (with the exception of MRI), and therefore no
woman would be denied any of the preventive
procedures because of lack of health insurance. We
have speculated that the differences exist because of
health care professionals’ acceptance and
recommendation of the preventive procedures; cultural
differences across Canada; and access (including cost
and availability). In this study we could not ascertain
the specific reason for the discrepancies across Canada,
but future research will address this important
question.
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